Brief: aTyr Pharma Announces Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
16/05/2022 13:13
May 16 (Reuters) - aTyr Pharma Inc LIFE.O :
* ATYR PHARMA ANNOUNCES PHASE 3 STUDY OF EFZOFITIMOD
(ATYR1923) IN
PULMONARY SARCOIDOSIS
* ATYR PHARMA INC - GLOBAL PIVOTAL EFZO-FIT™ STUDY EXPECTED
TO
BEGIN IN Q3 OF 2022
* ATYR PHARMA INC - PRIMARY ENDPOINT WILL EVALUATE STEROID
SPARING
EFFECT OF EFZOFITIMOD COMPARED TO PLACEBO
Source text for Eikon: ID:nGNX1bNNhL
Further company coverage: LIFE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan